Guardian Capital LP Vertex Pharmaceuticals Inc Transaction History

Guardian Capital LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 17, 2021	SELL	$207.02 - $241.31 $445,714 - $519,540	-2,153 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$207.01 - $276.09 $45,542 - $60,739	220 Added 11.38%	2,153 $509,000
Q3 2020 Nov 16, 2020	BUY	$255.65 - $303.1 $51,130 - $60,620	200 Added 11.54%	1,933 $526,000
Q2 2020 Aug 13, 2020	BUY	$225.48 - $295.8 $390,756 - $512,621	1,733 New	1,733 $503,000
Q4 2019 Feb 13, 2020	SELL	$166.71 - $223.91 $526,136 - $706,659	-3,156 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$166.23 - $187.09 $225,241 - $253,506	1,355 Added 75.24%	3,156 $535,000
Q2 2019 Aug 14, 2019	SELL	$164.61 - $190.37 $98,272 - $113,650	-597 Reduced 24.9%	1,801 $330,000
Q1 2019 May 15, 2019	SELL	$163.73 - $194.7 $59,106 - $70,286	-361 Reduced 13.08%	2,398 $441,000
Q4 2018 Feb 13, 2019	SELL	$151.91 - $192.21 $91,146 - $115,326	-600 Reduced 17.86%	2,759 $457,000
Q3 2018 Nov 13, 2018	SELL	$167.73 - $192.74 $110,198 - $126,630	-657 Reduced 16.36%	3,359 $647,000
Q2 2018 Aug 14, 2018	BUY	$145.72 - $169.96 $585,211 - $682,559	4,016 New	4,016 $683,000

1,723

222M

1.58M

1.36M

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $116B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

Get notified when there are updates to the investment portfolio of Guardian Capital LP, based on Form 13F filings with the SEC.

Stay updated on Guardian Capital LP with notifications on news.